CompletedPhase 1NCT04473911
Haplo Peripheral Blood Sct In GVHD Prevention
Studying Rare disorder potentially indicated for transplant or complication after transplantation
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Zachariah Michael DeFilipp
- Principal Investigator
- Zachariah DeFilipp, MDMassachusetts General Hospital
- Intervention
- FLUDARABINE(drug)
- Enrollment
- 25 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2020 – 2024
Study locations (1)
- Massachusetts General Hospital, Boston, Massachusetts, United States
Collaborators
Regimmune Corporation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04473911 on ClinicalTrials.govOther trials for Rare disorder potentially indicated for transplant or complication after transplantation
Additional recruiting or active studies for the same condition.